Trial Search Results

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Stanford Investigator(s):


  • Biological: sipuleucel-T


Inclusion Criteria:

   - subjects must be at least 18 years of age

   - subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent
   their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to

   - subjects must understand and sign an informed consent form

Exclusion Criteria:

   - none

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting